As pharmaceutical manufacturers continue to refine and adjust their compliance policies to meet a slew of regulations enacted over the past five years, they also are looking ahead and preparing for regulatory changes that could create many challenges. Six states have legislation that require pharmaceutical companies to report what they spend on physician sales, but the obligations differ in each state. The expectation is that many more states will follow. Additionally, New Hampshire has a prescription data restriction program. These initiatives have companies revisiting their compliance and marketing strategies to prepare for more changes. Compliance executives are looking to create flexible systems to keep up with the ever-changing environment…
Disclosure of Advertising and Marketing Spending
Pharma’s Response to Increased Regulatory Pressures
Sound Bites from the Field
Jann Torrance Balmer, RN, Ph.D., Director of Continuing Medical Education at the University of Virginia School of Medicine. For more information, visit healthsystem.virginia.edu.
Gary Fingerhut, Executive VP, Axentis Inc. For more information, visit axentis.com.
Darren Jones, CIA, Senior Manager, Healthcare Risk Consulting, Protiviti Inc. For more information, visit protiviti.com.
Peter Sandford, Executive VP, NXLevel Inc. For more information, visit nxlevel.com.
Wendy H. Schwartz, Esq., Partner, Reed Smith LLP. For more information, visit reedsmith.com.
A Positive Look at Compliance
William C. Bertrand Jr. Senior VP, General Counsel, Corporate Compliance, MedImmune Inc., Gaithersburg, Md.; MedImmune is dedicated to advancing science and medicine to help people live better lives and is focused on the areas of infectious diseases, cancer, and inflammatory diseases. For more information, visit medimmune.com.
Robert Freeman. U.S. Compliance Officer and Compliance Counsel, Serono Inc., Rockland, Mass.; Serono, with global headquarters in Geneva, is a biotechnology leader focused on reproductive health, neurology, metabolism, growth, and psoriasis. For more information, visit seronousa.com.
Steve Kanovsky. U.S. Corporate Compliance Officer, Sanofi-Aventis, Bridgewater, N.J.; Sanofi-Aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. For more information, visit sanofi-aventis.us.
Brent Saunders. Senior VP, Global Compliance and Business Practices, Schering-Plough Corp., Kenilworth, N.J.; Schering-Plough is a global science-based healthcare company with leading prescription, consumer, and animal health products. For more information, visit schering-plough.com.
Eric Siegel. VP, Deputy General Counsel, and Chief Compliance Officer, Cephalon Inc., Frazer, Pa.; Cephalon is a biopharmaceutical company that specializes in drugs to treat and manage neurological diseases, sleep disorders, cancer, and pain. For more information, visit cephalon.com.
Nagaraja Srivatsan. Head of Life Sciences, North America, Cognizant Technology Solutions, Teaneck, N.J.; Cognizant is a provider of information-technology services. For more information, visit cognizant.com.
Matt Wallach. Chief Marketing Officer, Health Market Science Inc., King of Prussia, Pa.; Health Market Science is a supplier of healthcare provider data in the United States. For more information, visit healthmarketscience.com.
Jim Zuffoletti. President and Cofounder, openQ Inc., Charlottesville, Va.; openQ develops and delivers solutions for the strategic management of key relationships across the life-sciences industry as well as other industries. For more information, visit openq.com.